BioNxt Secures EPO “Intention to Grant” for Revolutionary Sublingual Cladribine MS Therapy
BioNxt’s “Intention to Grant” from the EPO for a sublingual cladribine thin‑film could transform MS treatment and boost investor prospects.
4 minutes to read
BioNxt Solutions Inc. Achieves Proof-of-Concept for Semaglutide ODF and Settles Debt
BioNxt Solutions Inc. has made significant progress in its semaglutide oral dissolvable film program, completing proof-of-concept trials and reducing its debt by $225,010 through a settlement agreement.
2 minutes to read
BioNxt Solutions Inc. Secures European Patent for Innovative Anticancer Drug Delivery System
BioNxt Solutions Inc. has received a formal notice from the European Patent Office to grant a patent for its innovative anticancer drug delivery technology, a key milestone for the company’s lead product BNT23001.
2 minutes to read